UVADEX 20 Mikrogramm/ml Lösung zur Modifikation einer Blutfraktion

DRUG2 trials

Sponsors

Medical Center - University Of Freiburg

Conditions

Immune related adverse events induced by treatment with immunotherapysteroid-refractory chronic Graft-versus-Host-Disease

Phase 1

Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steriod-refractory immune related adverse events after immune checkpoint inhibitor therapy - ECIR

CompletedCTIS2024-513614-36-00

Medical Center - University Of FreiburgImmune related adverse events induced by treatment with immunotherapy

Start: 2022-07-27End: 2025-10-23Target: 30Updated: 2024-08-02

Phase 2

Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease (SR-cGvHD) - RUX-ECP

RecruitingCTIS2023-507754-33-00

Medical Center - University Of Freiburgsteroid-refractory chronic Graft-versus-Host-Disease

Start: 2025-02-19Target: 40Updated: 2026-01-21